Integrase Inhibitors
1 drugsAbout Integrase
Integrase is an enzyme essential for viral replication, responsible for integrating viral DNA into the host cell's genome. Inhibiting integrase prevents the virus from spreading within the body, making it a crucial drug target for certain viruses.
Integrase is a compelling target for therapeutic intervention due to its role in viral infection. Currently, there is no genetic evidence data available linking integrase to specific diseases, but its importance in viral replication makes it druggable.
Integrase is targeted by one FDA-approved drug, GENVOYA, a small molecule developed by Gilead Sciences. This drug falls into the 'Other' therapeutic area, indicating its relevance beyond common disease areas.
Top Integrase Drugs
Gilead Sciences is the only company with an approved drug targeting integrase.
The market is highly concentrated, suggesting high barriers to entry or a potential opportunity for new players with differentiated integrase inhibitors.
Integrase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Integrase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage and expand therapeutic options.
Integrase Clinical Trials 63 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Integrase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 30 | 3 | 1 | 91% |
| Phase 2 | 5 | 2 | 1 | 2 | 67% |
| Phase 3 | 7 | 6 | 1 | 0 | 86% |
| Phase 4 | 17 | 9 | 3 | 5 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Integrase Drug Approval Timeline (2015 - 2015)
The first and only drug, GENVOYA, was approved in 2015.
The lack of recent approvals indicates potential saturation or challenges in developing new integrase inhibitors, requiring innovative approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 43 (16 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Integrase. A trial counts if an approved drug acting on Integrase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.